Skip to main content
All lobbying filings

ACCENDRA HEALTH INC.

ACCENDRA HEALTH INC. filed a Q1 report for ACCENDRA HEALTH INC. on April 15, 2026.

Lobbying for ACCENDRA HEALTH INC.

All filings by ACCENDRA HEALTH INC. · Everything ACCENDRA HEALTH INC. has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 15, 2026
Expenses
$280,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Virginia

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4

Issues related to patient access to home medical equipment and related reimbursement.

Issues related to access to home medical equipment and related reimbursement (i.e., the "Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services [DIABETES] Act" (S. 4307) and the "DMEPOS Relief Act of 2025" [H.R. 2005, S. 2951]; and competitive bidding, the "Supplemental Oxygen Access Reform [SOAR] Act of 2025" [H.R. 2902, S. 1406]); promoting electronic prescribing platforms; and diabetes management and related durable medical equipment reimbursement channels.

FY 2027 Appropriations.

CHAMPVA medical supply reimbursement.

 Bills named in this filing 5

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem